174 related articles for article (PubMed ID: 24868139)
1. The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1.
Li J; Cui Y; Wang Q; Guo D; Pan X; Wang X; Bi H; Chen W; Liu Z; Zhao S
Mol Vis; 2014; 20():649-60. PubMed ID: 24868139
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of a Brown Seaweed Extract from
Dörschmann P; Schmitt C; Bittkau KS; Neupane S; Synowitz M; Roider J; Alban S; Held-Feindt J; Klettner A
Mar Drugs; 2020 Dec; 18(12):. PubMed ID: 33302412
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2.
Kernt M; Thiele S; Neubauer AS; Koenig S; Hirneiss C; Haritoglou C; Ulbig MW; Kampik A
Retina; 2012 Sep; 32(8):1652-63. PubMed ID: 22466477
[TBL] [Abstract][Full Text] [Related]
4. Fluocinolone inhibits VEGF expression via glucocorticoid receptor in human retinal pigment epithelial (ARPE-19) cells and TNF-alpha-induced angiogenesis in chick chorioallantoic membrane (CAM).
Ayalasomayajula SP; Ashton P; Kompella UB
J Ocul Pharmacol Ther; 2009 Apr; 25(2):97-103. PubMed ID: 19284324
[TBL] [Abstract][Full Text] [Related]
5. Comparative antiproliferative and cytotoxic profile of bevacizumab (Avastin), pegaptanib (Macugen) and ranibizumab (Lucentis) on different ocular cells.
Spitzer MS; Yoeruek E; Sierra A; Wallenfels-Thilo B; Schraermeyer U; Spitzer B; Bartz-Schmidt KU; Szurman P
Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1837-42. PubMed ID: 17347807
[TBL] [Abstract][Full Text] [Related]
6. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture.
Malik D; Tarek M; Caceres del Carpio J; Ramirez C; Boyer D; Kenney MC; Kuppermann BD
Br J Ophthalmol; 2014 Jun; 98 Suppl 1(Suppl 1):i11-16. PubMed ID: 24836865
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor induces VEGF expression via activation of the Wnt/β-catenin signaling pathway in ARPE-19 cells.
Wang Y; Sang A; Zhu M; Zhang G; Guan H; Ji M; Chen H
Mol Vis; 2016; 22():886-97. PubMed ID: 27499609
[TBL] [Abstract][Full Text] [Related]
8. Differential effects of bevacizumab, ranibizumab and aflibercept on cell viability, phagocytosis and mitochondrial bioenergetics of retinal pigment epithelial cell.
Sheu SJ; Chao YM; Liu NC; Chan JY
Acta Ophthalmol; 2015 Dec; 93(8):e631-43. PubMed ID: 25975662
[TBL] [Abstract][Full Text] [Related]
9. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
[TBL] [Abstract][Full Text] [Related]
10. Comparison of choroidal and retinal endothelial cells: characteristics and response to VEGF isoforms and anti-VEGF treatments.
Stewart EA; Samaranayake GJ; Browning AC; Hopkinson A; Amoaku WM
Exp Eye Res; 2011 Nov; 93(5):761-6. PubMed ID: 21970900
[TBL] [Abstract][Full Text] [Related]
11. Decorin inhibits angiogenic potential of choroid-retinal endothelial cells by downregulating hypoxia-induced Met, Rac1, HIF-1α and VEGF expression in cocultured retinal pigment epithelial cells.
Du S; Wang S; Wu Q; Hu J; Li T
Exp Eye Res; 2013 Nov; 116():151-60. PubMed ID: 24016866
[TBL] [Abstract][Full Text] [Related]
12. Response to anti-VEGF-A treatment of retinal pigment epithelial cells in vitro.
Puddu A; Sanguineti R; Traverso CE; Viviani GL; Nicolò M
Eur J Ophthalmol; 2016 Aug; 26(5):425-30. PubMed ID: 27079208
[TBL] [Abstract][Full Text] [Related]
13. Effects of Bevacizumab, Ranibizumab, and Aflibercept on MicroRNA Expression in a Retinal Pigment Epithelium Cell Culture Model of Oxidative Stress.
Dinç E; Ayaz L; Kurt AH
J Ocul Pharmacol Ther; 2018 May; 34(4):346-353. PubMed ID: 29389239
[TBL] [Abstract][Full Text] [Related]
14. Aflibercept, bevacizumab and ranibizumab prevent glucose-induced damage in human retinal pericytes in vitro, through a PLA2/COX-2/VEGF-A pathway.
Giurdanella G; Anfuso CD; Olivieri M; Lupo G; Caporarello N; Eandi CM; Drago F; Bucolo C; Salomone S
Biochem Pharmacol; 2015 Aug; 96(3):278-87. PubMed ID: 26056075
[TBL] [Abstract][Full Text] [Related]
15. Role of IL-8 induced angiogenesis in uveal melanoma.
Lattanzio L; Tonissi F; Torta I; Gianello L; Russi E; Milano G; Merlano M; Lo Nigro C
Invest New Drugs; 2013 Oct; 31(5):1107-14. PubMed ID: 23912257
[TBL] [Abstract][Full Text] [Related]
16. Effects of VEGF inhibitors on human retinal pigment epithelium under high glucose and hypoxia.
Bahrami B; Shen W; Zhu L; Zhang T; Chang A; Gillies MC
Clin Exp Ophthalmol; 2019 Nov; 47(8):1074-1081. PubMed ID: 31265210
[TBL] [Abstract][Full Text] [Related]
17. Effects of concentration of amyloid β (Aβ) on viability of cultured retinal pigment epithelial cells.
Masuda N; Tsujinaka H; Hirai H; Yamashita M; Ueda T; Ogata N
BMC Ophthalmol; 2019 Mar; 19(1):70. PubMed ID: 30849957
[TBL] [Abstract][Full Text] [Related]
18. Autocrine impact of VEGF-A on uveal melanoma cells.
Koch KR; Refaian N; Hos D; Schlereth SL; Bosch JJ; Cursiefen C; Heindl LM
Invest Ophthalmol Vis Sci; 2014 Apr; 55(4):2697-704. PubMed ID: 24677103
[TBL] [Abstract][Full Text] [Related]
19. Gene profiling of human VEGF signaling pathways in human endothelial and retinal pigment epithelial cells after anti VEGF treatment.
Golan S; Entin-Meer M; Semo Y; Maysel-Auslender S; Mezad-Koursh D; Keren G; Loewenstein A; Barak A
BMC Res Notes; 2014 Sep; 7():617. PubMed ID: 25201034
[TBL] [Abstract][Full Text] [Related]
20. Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions.
Saenz-de-Viteri M; Fernández-Robredo P; Hernández M; Bezunartea J; Reiter N; Recalde S; García-Layana A
Biochem Pharmacol; 2016 Mar; 103():129-39. PubMed ID: 26793998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]